BioCentury
ARTICLE | Clinical News

Viking's VK2809 meets in Phase II for NAFLD

September 21, 2018 4:39 PM UTC

Viking Therapeutics Inc. (NASDAQ:VKTX) reported that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). The company plans to meet with FDA early next year to discuss next steps for the liver-selective thyroid hormone receptor β agonist. On a conference call, Viking said it expects FDA will also require biopsy data from an additional Phase II trial before it can move to Phase III testing.

The double-blind, U.S. Phase II trial enrolled 45 patients with elevated LDL-C and NAFLD to receive placebo or 10 mg oral VK2809 daily or every other day. On the primary endpoint, both dose regimens of VK2809 significantly reduced LDL-C by at least 20% from baseline to week 12 vs. placebo...